Development and validation of a supervised deep learning algorithm for automated whole-slide programmed death-ligand 1 tumour proportion score assessment in non-small cell lung cancer

被引:28
|
作者
Hondelink, Liesbeth M. [1 ]
Huyuk, Melek [2 ]
Postmus, Pieter E. [2 ]
Smit, Vincent T. H. B. M. [1 ]
Blom, Sami [3 ]
von der Thusen, Jan H. [4 ]
Cohen, Danielle [1 ]
机构
[1] Leiden Univ, Dept Pathol, Med Ctr, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands
[2] Leiden Univ, Dept Pulmonol, Med Ctr, Leiden, Netherlands
[3] Aiforia Technol Oy, Helsinki, Finland
[4] Erasmus MC, Dept Pathol, Rotterdam, Netherlands
关键词
artificial intelligence; computational pathology; immunotherapy; non-small cell lung cancer; programmed death-ligand 1; PD-L1; IMMUNOHISTOCHEMISTRY; PEMBROLIZUMAB;
D O I
10.1111/his.14571
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Aims Immunohistochemical programmed death-ligand 1 (PD-L1) staining to predict responsiveness to immunotherapy in patients with advanced non-small cell lung cancer (NSCLC) has several drawbacks: a robust gold standard is lacking, and there is substantial interobserver and intraobserver variance, with up to 20% discordance around cutoff points. The aim of this study was to develop a new deep learning-based PD-L1 tumour proportion score (TPS) algorithm, trained and validated on a routine diagnostic dataset of digitised PD-L1 (22C3, laboratory-developed test)-stained samples. Methods and results We designed a fully supervised deep learning algorithm for whole-slide PD-L1 assessment, consisting of four sequential convolutional neural networks (CNNs), using aiforia create software. We included 199 whole slide images (WSIs) of 'routine diagnostic' histology samples from stage IV NSCLC patients, and trained the algorithm by using a training set of 60 representative cases. We validated the algorithm by comparing the algorithm TPS with the reference score in a held-out validation set. The algorithm had similar concordance with the reference score (79%) as the pathologists had with one another (75%). The intraclass coefficient was 0.96 and Cohen's kappa coefficient was 0.69 for the algorithm. Around the 1% and 50% cutoff points, concordance was also similar between pathologists and the algorithm. Conclusions We designed a new, deep learning-based PD-L1 TPS algorithm that is similarly able to assess PD-L1 expression in daily routine diagnostic cases as pathologists. Successful validation on routine diagnostic WSIs and detailed visual feedback show that this algorithm meets the requirements for functioning as a 'scoring assistant'.
引用
收藏
页码:635 / 647
页数:13
相关论文
共 50 条
  • [1] Programmed death-ligand 1 immunohistochemistry testing for non-small cell lung cancer in practice
    Mino-Kenudson, Mari
    CANCER CYTOPATHOLOGY, 2017, 125 (07) : 521 - 528
  • [2] A Multi-Institutional Study to Evaluate Automated Whole Slide Scoring of Immunohistochemistry for Assessment of Programmed Death-Ligand 1 (PD-L1) Expression in Non-Small Cell Lung Cancer
    Taylor, Clive R.
    Jadhav, Anagha P.
    Gholap, Abhi
    Kamble, Gurunath
    Huang, Jiaoti
    Gown, Allen
    Doshi, Isha
    Rimm, David L.
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2019, 27 (04) : 263 - 269
  • [3] Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer
    Khunger, Monica
    Rakshit, Sagar
    Pasupuleti, Vinay
    Hernandez, Adrian V.
    Mazzone, Peter
    Stevenson, James
    Pennell, Nathan A.
    Velcheti, Vamsidhar
    CHEST, 2017, 152 (02) : 271 - 281
  • [4] Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancer
    Nam, Chang Hyun
    Koh, Jaemoon
    Ock, Chan-Young
    Kim, Miso
    Keam, Bhumsuk
    Kim, Tae Min
    Jeon, Yoon Kyung
    Kim, Dong-Wan
    Chung, Doo Hyun
    Heo, Dae Seog
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2021, 36 (04): : 975 - +
  • [5] Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-small Cell Lung Cancer
    Takamori, Shinkichi
    Toyokawa, Gouji
    Okamoto, Isamu
    Takada, Kazuki
    Kozuma, Yuka
    Matsubara, Taichi
    Haratake, Naoki
    Akamine, Takaki
    Katsura, Masakazu
    Mukae, Nobutaka
    Shoji, Fumihiro
    Okamoto, Tatsuro
    Oda, Yoshinao
    Iwaki, Toru
    Iihara, Koji
    Nakanishi, Yoichi
    Maehara, Yoshihiko
    ANTICANCER RESEARCH, 2017, 37 (08) : 4223 - 4228
  • [6] Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
    Iafolla, Marco A. J.
    Juergens, Rosalyn A.
    FRONTIERS IN ONCOLOGY, 2017, 7
  • [7] Programmed death-ligand 1 testing in patients with non-small cell lung cancer: Ready for prime time?
    Gainor, Justin F.
    CANCER CYTOPATHOLOGY, 2017, 125 (08) : 591 - 593
  • [8] Relationship Between Programmed Death-ligand 1 and Clinicopathological Characteristics in Non-small Cell Lung Cancer Patients
    Yan-yan Chen
    Liu-bo Wang
    Hui-li Zhu
    Xiang-yang Li
    Yan-ping Zhu
    Yu-lei Yin
    Fan-zhen Lü
    Zi-li Wang
    Jie-ming Qu
    Chinese Medical Sciences Journal, 2013, 28 (03) : 147 - 151
  • [9] Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?
    Acheampong, Emmanuel
    Spencer, Isaac
    Lin, Weitao
    Ziman, Melanie
    Millward, Michael
    Gray, Elin
    CANCERS, 2019, 11 (07)
  • [10] Cell Block as a Surrogate for Programmed Death-Ligand 1 Staining Testing in Patients of Non-Small Cell Lung Cancer
    Dong, Zhengwei
    Liu, Yiwei
    Jiang, Tao
    Hou, Likun
    Wu, Fengying
    Gao, Guanghui
    Li, Xuefei
    Zhao, Chao
    Wang, Yan
    Yang, Shuo
    Mao, Shiqi
    Liu, Qian
    Li, Yumei
    Xu, Chuan
    Wu, Chunyan
    Ren, Shengxiang
    Zhou, Caicun
    Zhang, Jun
    Hirsch, Fred R.
    JOURNAL OF CANCER, 2020, 11 (03): : 551 - 558